Table 1 Baseline characteristics across prescriber adoption categories
From: Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
Adoption Category | Laggards n = 1077(SD) | Late Majority n = 2273 | Early Majority n = 2294 | Early Adopters n = 915 | Innovators n = 153 |
|---|---|---|---|---|---|
RegionsΔ n (%) | |||||
Northeast | 327 (15.1%) | 721 (33.4%) | 756 (35.0%) | 308 (14.3%) | 49 (2.3%) |
Midwest | 165 (17.5%) | 327 (34.6%) | 318 (33.7%) | 117 (12.4%) | 18 (1.9%) |
South | 403 (16.0%) | 878 (34.8%) | 840 (33.3%) | 345 (13.7%) | 56 (2.2%) |
West | 182 (16.8%) | 347 (32.0%) | 380 (35.1%) | 145 (13.4%) | 30 (2.8%) |
Gender* n (%) | |||||
Female | 317 (16.8%) | 657 (34.8%) | 581 (30.8%) | 279 (14.8%) | 52 (2.8%) |
Specialty Category** n (%) | |||||
Primary Care | 291 (17.3%) | 613 (36.4%) | 494 (29.3%) | 239 (14.2%) | 48 (2.8%) |
Regular Specialists (other than Infectious Disease specialists, and Gastroenterologists & Hepatologists) | 58 (14.3%) | 158 (38.9%) | 136 (33.5%) | 46 (11.3%) | 8 (2.0%) |
Infectious Disease Specialists | 126 (18.6%) | 227 (33.5%) | 224 (33.0%) | 87 (12.8%) | 14 (2.1%) |
Gastroenterologists & Hepatologists | 602 (15.3%) | 1275 (32.3%) | 1440 (36.5%) | 543 (13.8%) | 83 (2.1%) |
Median Income (by Zip Code)Δ | |||||
Median Income (by Zip Code) | 5.83 (2.63) | 5.87 (2.69) | 5.77 (2.59) | 5.99 (2.90) | 6.32 (2.95) |